David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.
Taken together, these three responses point to gaps beyond the next therapy: in how academic medicine is valued, in what ...
Timothy Janetos, MD, explained when to refer uveitis to a specialist and why access to uveitis care remains limited.
The FDA has approved Enspryng (satralizumab, Genentech) for thyroid eye disease (TED), making the drug the first subcutaneous ...
At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic ...
Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point ...
A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.
Restoring sight after whole human eye transplant remains a long-term goal, and the optic nerve is the limiting factor, ...
Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...
David F. Chang, MD, explained how offering complementary refractive IOLs reduces patient anxiety and indecision.
Ryzumvi (phentolamine ophthalmic solution 0.75%) is approved for the treatment of presbyopia in adults. It is also approved for pharmacologically induced mydriasis produced by adrenergic agonists or ...
Kenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results